JPH10508491A - 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 - Google Patents
新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法Info
- Publication number
- JPH10508491A JPH10508491A JP8515542A JP51554296A JPH10508491A JP H10508491 A JPH10508491 A JP H10508491A JP 8515542 A JP8515542 A JP 8515542A JP 51554296 A JP51554296 A JP 51554296A JP H10508491 A JPH10508491 A JP H10508491A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- region
- adenovirus
- virus
- adeno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 188
- 239000013598 vector Substances 0.000 title claims abstract description 116
- 238000004806 packaging method and process Methods 0.000 title claims abstract description 90
- 238000000034 method Methods 0.000 title claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 164
- 238000012217 deletion Methods 0.000 claims abstract description 131
- 230000037430 deletion Effects 0.000 claims abstract description 128
- 108700019146 Transgenes Proteins 0.000 claims abstract description 51
- 101150066038 E4 gene Proteins 0.000 claims abstract description 37
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 360
- 241000700605 Viruses Species 0.000 claims description 144
- 239000013612 plasmid Substances 0.000 claims description 87
- 241001135569 Human adenovirus 5 Species 0.000 claims description 73
- 241000702421 Dependoparvovirus Species 0.000 claims description 72
- 108020004414 DNA Proteins 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 49
- 108700026244 Open Reading Frames Proteins 0.000 claims description 30
- 108010032856 inhibin-alpha subunit Proteins 0.000 claims description 29
- 230000012010 growth Effects 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 230000001939 inductive effect Effects 0.000 claims description 23
- 230000035772 mutation Effects 0.000 claims description 22
- 230000002950 deficient Effects 0.000 claims description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 101150066583 rep gene Proteins 0.000 claims description 19
- 101150005585 E3 gene Proteins 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000013603 viral vector Substances 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 9
- 210000003292 kidney cell Anatomy 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 101150044789 Cap gene Proteins 0.000 claims description 6
- 101001049954 Human adenovirus C serotype 2 Early 4 ORF6 protein Proteins 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 210000005260 human cell Anatomy 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 4
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 4
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 4
- 208000016361 genetic disease Diseases 0.000 claims description 4
- 230000002068 genetic effect Effects 0.000 claims description 4
- 230000003362 replicative effect Effects 0.000 claims description 4
- 208000037919 acquired disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 230000008093 supporting effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 102200157658 rs1555229948 Human genes 0.000 claims 22
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 3
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 3
- 101710087110 ORF6 protein Proteins 0.000 claims 3
- 101710095001 Uncharacterized protein in nifU 5'region Proteins 0.000 claims 3
- 102000053602 DNA Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003145 cytotoxic factor Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 abstract description 7
- 231100000518 lethal Toxicity 0.000 abstract description 7
- 230000001665 lethal effect Effects 0.000 abstract description 7
- 108010018673 Adenovirus Early Proteins Proteins 0.000 abstract 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 66
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 36
- 208000015181 infectious disease Diseases 0.000 description 36
- 239000000523 sample Substances 0.000 description 34
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 33
- 239000000047 product Substances 0.000 description 30
- 238000010276 construction Methods 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 21
- 230000006870 function Effects 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 14
- 239000000893 inhibin Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 108010004250 Inhibins Proteins 0.000 description 11
- 102000002746 Inhibins Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 230000010354 integration Effects 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 101150029662 E1 gene Proteins 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 239000013607 AAV vector Substances 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 7
- 101710096438 DNA-binding protein Proteins 0.000 description 7
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 6
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 102000018832 Cytochromes Human genes 0.000 description 4
- 108010052832 Cytochromes Proteins 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000000975 co-precipitation Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000005745 host immune response Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 3
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 3
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101710094396 Hexon protein Proteins 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 108010061971 Inhibin-beta Subunits Proteins 0.000 description 3
- 102000012407 Inhibin-beta Subunits Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 2
- 101100409308 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) adv-1 gene Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101150083026 ORF36 gene Proteins 0.000 description 2
- 101150007210 ORF6 gene Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710197985 Probable protein Rev Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- -1 α-gonadotrophin Proteins 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700015125 Adenovirus DBP Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101150082674 E2 gene Proteins 0.000 description 1
- 101100388577 Escherichia coli ebr gene Proteins 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241000701149 Human adenovirus 1 Species 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 241000702377 Inovirus Species 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101100028161 Porcine circovirus 2 ORF4 gene Proteins 0.000 description 1
- 101710132686 Protein L3 Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101710136899 Replication enhancer protein Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000006658 host protein synthesis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220219006 rs1060501597 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000576 supplementary effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
- C12N2710/10362—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.誘導プロモーターに機能しうる状態で連結された、細胞障害性タンパク質を コードするアデノウイルス遺伝子または遺伝子領域を含んでなるDNAプラスミ ド。 2.前記のアデノウイルス遺伝子または遺伝子領域がE2A遺伝子またはE4遺 伝子領域から選択される、請求項1に記載のDNAプラスミド。 3.誘導プロモーターに機能しうる状態で連結された、タンパク質をコードする アデノ随伴ウイルス遺伝子を含んでなるDNAプラスミド。 4.前記のアデノ随伴ウイルス遺伝子がrep遺伝子領域およびcap遺伝子領 域から選択される、請求項3に記載のDNAプラスミド。 5.アデノ随伴ウイルスのRepタンパク質の1つをコードし、かつ誘導プロモ ーターに機能しうる状態で連結されたアデノ随伴ウイルス遺伝子を含んでなるD NAプラスミド。 6.前記の誘導プロモーターがcAMP応答要素結合性タンパク質により調節さ れる遺伝子からのプロモーターである、請求項1〜5のいずれか1項に記載のD NAプラスミド。 7.前記の誘導プロモーターが哺乳動物αインヒビンをコードする遺伝子から選 択される、請求項1〜5のいずれか1項に記載のDNAプラスミド。 8.前記の誘導プロモーターがマウスαインヒビンをコードする遺伝子から選択 される、請求項1〜5のいずれか1項に記載のDNAプラスミド。 9.前記の誘導プロモーターがテトラサイクリン応答プロモーターをコードする 遺伝子から選択される、請求項1〜5のいずれか1項に記載のDNAプラスミド 。 10.ATCC#75879を指定されたプラスミドpIK6.1MIP(α)− E4。 11.ウイルス構造遺伝子、E1、E2A、E4初期遺伝子領域よりなる群から選 択される少なくとも2つの欠失、少なくとも2つの変異、または少なくとも1つ の変異と1つの欠失を有し、場合によりE3遺伝子領域の欠失を含んでいて もよい複製欠損性の変異型アデノウイルスの増殖を支持するパッケージング細胞 系。 12.ウイルス構造遺伝子、E1、E2A、E4初期遺伝子領域よりなる群から選 択される少なくとも2つの欠失、2つの変異、または1つの欠失と1つの変異を 有し、場合によりE3遺伝子領域の欠失を含んでいてもよく、さらに前記の欠失 のいずれか1つと置き換わるトランスジーンを含有する組換えアデノウイルスベ クターの増殖を支持するパッケージング細胞系。 13.ヘルパーアデノウイルスを伴っていない複製欠損性の変異型アデノ随伴ウイ ルスの増殖を支持するパッケージング細胞系であって、ウイルス関連RNAをコ ードするDNA配列、E1、E2AおよびE4初期遺伝子領域を含んでなるパッ ケージング細胞系。 14.ヘルパーアデノウイルスを伴っていない複製欠損性の組換えアデノ随伴ウイ ルスの増殖を支持するパッケージング細胞系であって、ウイルス関連RNA配列 、E1、E2AおよびE4初期遺伝子領域を含んでなるパッケージング細胞系。 15.ヘルパーアデノウイルスを伴っていない、アデノ随伴ウイルスrep遺伝子 領域の欠失を有する複製欠損性の変異型アデノ随伴ウイルスの増殖を支持するパ ッケージング細胞系であって、ウイルス関連RNA配列、E1、E2A、E4初 期遺伝子領域、アデノ随伴ウイルスrep遺伝子領域、および場合によりE3初 期遺伝子領域を含んでなるパッケージング細胞系。 16.ヘルパーアデノウイルスを伴っていない、アデノ随伴ウイルスrep遺伝子 領域の欠失を有する複製欠損性の組換えアデノ随伴ウイルスを産生するパッケー ジング細胞系であって、ウイルス関連RNAをコードするDNA配列、E1、E 2A、E4初期遺伝子領域、アデノ随伴ウイルスrep遺伝子領域、および場合 によりE3初期領域を含んでなるパッケージング細胞系。 17.ヘルパーアデノウイルスを伴っていない、アデノ随伴ウイルスrep遺伝子 領域の欠失を有する複製欠損性の変異型アデノ随伴ウイルスの増殖を支持するパ ッケージング細胞系であって、ウイルス関連RNA配列、E1、E2A、E4初 期遺伝子領域、アデノ随伴ウイルスrep遺伝子領域、アデノ随伴ウイル スcap遺伝子領域、および場合によりE3初期遺伝子領域を含んでなるパッケ ージング細胞系。 18.ヘルパーアデノウイルスを伴っていない、アデノ随伴ウイルスrep遺伝子 領域の欠失を有する複製欠損性の組換えアデノ随伴ウイルスを産生するパッケー ジング細胞系であって、ウイルス関連RNAをコードするDNA配列、E1、E 2A、E4初期遺伝子領域、アデノ随伴ウイルスrep遺伝子領域、アデノ随伴 ウイルスcap遺伝子領域、および場合によりE3初期遺伝子領域を含んでなる パッケージング細胞系。 19.ウイルス構造遺伝子、E1、E2A、E4初期遺伝子領域よりなる群から選 択される少なくとも2つの欠失、少なくとも2つの変異、または少なくとも1つ の変異と1つの欠失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよ い、請求項11に記載のパッケージング細胞系において産生される複製欠損性の 変異型アデノウイルス。 20.ウイルス構造遺伝子、E1、E2A、E4初期遺伝子領域よりなる群から選 択される少なくとも2つの欠失、少なくとも2つの変異、または少なくとも1つ の変異と1つの欠失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよ い、複製欠損性の変異型アデノウイルス。 21.ウイルス構造遺伝子配列、E1、E2A、E4初期遺伝子領域よりなる群か ら選択される少なくとも2つの欠失、少なくとも2つの変異、または少なくとも 1つの変異と1つの欠失を有し、場合によりE3遺伝子領域の欠失を含んでいて もよい組換えアデノウイルスベクターであって、前記の欠失のいずれか1つと置 き換わるトランスジーンをさらに含有し、請求項12に記載のパッケージング細 胞系から産生される組換えアデノウイルスベクター。 22.ウイルス構造遺伝子、E1、E2A、E4初期遺伝子領域よりなる群から選 択される少なくとも2つの欠失、少なくとも2つの変異、または少なくとも1つ の変異と1つの欠失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよ い組換えアデノウイルスベクターであって、前記の欠失のいずれか1つと置き換 わるトランスジーンをさらに含有する組換えアデノウイルスベクター。 23.E1、E2A、E4初期遺伝子領域、およびウイルス関連RNAをコードす るDNA配列を含んでなるパッケージング細胞系において増殖する、ヘルパーア デノウイルスを伴っていない複製欠損性の変異型アデノ随伴ウイルス。 24.ウイルス関連RNA配列、E1、E2A、E4初期遺伝子領域、および場合 によりE3初期遺伝子領域を含んでなるパッケージング細胞系において増殖する 、ヘルパーアデノウイルスを伴っていない複製欠損性の組換えアデノウイルスベ クター。 25.ウイルス関連RNAをコードするDNA配列、E1、E2A、E4初期遺伝 子領域、アデノ随伴ウイルスrep遺伝子領域、および場合によりE3初期遺伝 子領域を含んでなるパッケージング細胞系において増殖する複製欠損性の変異型 アデノ随伴ウイルスであって、アデノ随伴ウイルスrep遺伝子領域の欠失を有 し、かつヘルパーアデノウイルスを伴っていない変異型アデノ随伴ウイルス。 26.ウイルス関連RNAをコードするDNA配列、E1、E2A、E4初期遺伝 子領域、アデノ随伴ウイルスrep遺伝子領域、および場合によりE3初期遺伝 子領域を含んでなるパッケージング細胞系において増殖する複製欠損性の組換え アデノ随伴ウイルスベクターであって、アデノ随伴ウイルスrep遺伝子領域の 欠失を有し、かつヘルパーアデノウイルスを伴わず、さらに前記の欠失と置き換 わるトランスジーンを含有する組換えアデノ随伴ウイルスベクター。 27.ウイルス関連RNAをコードするDNA配列、E1、E2A、E4初期遺伝 子領域、アデノ随伴ウイルスrep遺伝子領域、アデノ随伴ウイルスcap遺伝 子領域、および場合によりE3初期遺伝子領域を含んでなるパッケージング細胞 系において増殖する複製欠損性の変異型アデノ随伴ウイルスであって、アデノ随 伴ウイルスrep遺伝子領域の欠失を有し、かつヘルパーアデノウイルスを伴っ ていない変異型アデノ随伴ウイルス。 28.ウイルス関連RNAをコードするDNA配列、E1、E2A、E4初期遺伝 子領域、アデノ随伴ウイルスrep遺伝子領域、アデノ随伴ウイルスcap遺伝 子領域、および場合によりE3初期遺伝子領域を含んでなるパッケージング細胞 系において増殖する複製欠損性の組換えアデノ随伴ウイルスベクターであって、 アデノ随伴ウイルスrep遺伝子領域の欠失を有し、かつヘルパーアデ ノウイルスを伴わず、さらに前記の欠失と置き換わるトランスジーンを含有する 組換えアデノ随伴ウイルスベクター。 29.哺乳動物の標的細胞に、トランスジーンを含有する組換えアデノウイルスま たはアデノ随伴ウイルスを感染させる方法であって、 i.該標的細胞に、所定のトランスジーンを担う請求項21、22、24、 26または28に記載の組換えウイルスベクターを感染させ、そして ii.該標的細胞において該トランスジーンを発現させる、 各工程を含んでなる方法。 30.請求項29に記載の方法により生産されるトランスジーンを感染させた哺乳 動物標的細胞。 31.前記の細胞が複製ヒト細胞、遅延複製ヒト細胞または非複製ヒト細胞よりな る群から選択される、請求項30に記載の標的細胞。 32.ATCC#CRL11711を指定されたヒト胚腎細胞由来のパッケージン グ細胞系。 33.遺伝病または後天性疾患の治療方法であって、 i.治療用遺伝子からなるトランスジーンを含有する請求項21、22、2 4、26または28に記載のアデノウイルス由来またはアデノ随伴ウイ ルス由来の組換えベクターを医薬として許容される用量で標的細胞に投 与し、そして ii.該標的細胞において該治療用遺伝子を発現させて、遺伝病または後天性 疾患を軽減させる、 各工程を含んでなる方法。 34.請求項21、22、24、26、28、36、55、57、59、60また は62に記載のアデノウイルス由来またはアデノ随伴ウイルス由来の組換えベク ター、および製剤学的に許容される担体を含有するワクチン。 35.E1およびE4初期遺伝子領域よりなる群から選択される少なくとも2つの 欠失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよく、さらに前記 の欠失のいずれか1つと置き換わるトランスジーンを含有するアデノウイルスベ クターの増殖を支持するパッケージング細胞系。 36.E1およびE4初期遺伝子領域よりなる群から選択される少なくとも2つの 欠失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよく、さらに前記 の欠失のいずれか1つと置き換わるトランスジーンを含有する組換えアデノウイ ルスベクター。 37.誘導プロモーターに機能しうる状態で連結されたアデノウイルス遺伝子断片 E4オープンリーディングフレームORF6を含んでなるDNAプラスミド。 38.前記の誘導プロモーターがcAMP応答要素結合性タンパク質により調節さ れる遺伝子から選択されたプロモーターである、請求項37に記載のDNAプラ スミド。 39.前記の誘導プロモーターが哺乳動物αインヒビンをコードする遺伝子から選 択される、請求項38に記載のDNAプラスミド。 40.前記の誘導プロモーターがマウスαインヒビンに由来するものである、請求 項39に記載のDNAプラスミド。 41.前記の誘導プロモーターが薬剤誘導可能なテトラサイクリン応答プロモータ ーである、請求項37に記載のDNAプラスミド。 42.ATCC# を指定されたプラスミドpIK6.1MIP(α) −E4 ORF6。 43.誘導プロモーターに機能しうる状態で連結されたアデノウイルス遺伝子E2 Aを含んでなるDNAプラスミド。 44.前記の誘導プロモーターがcAMP応答要素結合性タンパク質により調節さ れる遺伝子から選択されたプロモーターである、請求項43に記載のDNAプラ スミド。 45.前記の誘導プロモーターが哺乳動物αインヒビンをコードする遺伝子から選 択される、請求項44に記載のDNAプラスミド。 46.前記の誘導プロモーターがマウスαインヒビンに由来するものである、請求 項45に記載のDNAプラスミド。 47.前記の誘導プロモーターが薬剤誘導可能なテトラサイクリン応答プロモータ ーである、請求項45に記載のDNAプラスミド。 48.ATCC# を指定されたプラスミドpIK6.1MIP(α) −E2A。 49.E1、E2A、E4−ORF6初期領域よりなる群から選択される少なくと も2つの欠失、少なくとも2つの変異、または少なくとも1つの変異と1つの欠 失を有し、場合によりE3遺伝子領域の欠失を含んでいてもよい、複製欠損性の 変異型アデノウイルスまたは組換えアデノウイルスベクター(該組換えアデノウ イルスベクターはさらに前記の欠失のいずれか1つと置き換わるトランスジーン を含有する)の増殖を支持するパッケージング細胞系。 50.E1およびE4−ORF6初期遺伝子領域からの2つの欠失を有し、場合に よりE3遺伝子領域の欠失を含んでいてもよい、複製欠損性の変異型アデノウイ ルスまたは組換えアデノウイルスベクター(該組換えアデノウイルスベクターは さらに前記の欠失のいずれか1つと置き換わるトランスジーンを含有する)の増 殖を支持するパッケージング細胞系。 51.#CRL を指定された、アデノウイルス5 E4 ORF6 DNA遺伝子断片でトランスフェクトされたヒト胚腎細胞由来のパッケージング 細胞系。 52.E1およびE2A初期遺伝子領域からの2つの欠失を有し、場合によりE3 遺伝子領域の欠失を含んでいてもよい、複製欠損性の変異型アデノウイルスまた は組換えアデノウイルスベクター(該組換えアデノウイルスベクターはさらに前 記の欠失のいずれか1つと置き換わるトランスジーンを含有する)の増殖を支持 するパッケージング細胞系。 53.テトラサイクリン応答プロモーターに機能しうる状態で連結された1以上の アデノウイルス後期遺伝子領域を含んでなるDNAプラスミド。 54.前記のアデノウイルス後期遺伝子領域がL1、L2、L3、L4またはL5 から選択される、請求項53に記載のDNAプラスミド。 55.E1およびE4初期遺伝子領域からの2つの欠失を有し、場合によりE3遺 伝子領域の欠失を含んでいてもよく、さらに前記の欠失のいずれかと置き換わる トランスジーンを含有する、組換えアデノウイルスベクター。 56.E1およびE4初期遺伝子領域からの2つの欠失を有し、場合によりE3遺 伝子領域の欠失を含んでいてもよい、複製欠損性の変異型アデノウイルス。 57.E1、E2AおよびE4初期遺伝子領域からの3つの欠失を有し、場合によ りE3遺伝子領域の欠失を含んでいてもよく、さらに前記の欠失のいずれかと置 き換わるトランスジーンを含有する、組換えアデノウイルスベクター。 58.E1、E2AおよびE4初期遺伝子領域からの3つの欠失を有し、場合によ りE3遺伝子領域の欠失を含んでいてもよい、複製欠損性の変異型アデノウイル ス。 59.E1およびE2A初期遺伝子領域からの2つの欠失を有し、場合によりE3 遺伝子領域の欠失を含んでいてもよく、さらに前記の欠失のいずれかと置き換わ るトランスジーンを含有する、組換えアデノウイルスベクター。 60.E1およびE2A初期遺伝子領域からの2つの欠失を有し、場合によりE3 遺伝子領域の欠失を含んでいてもよい、複製欠損性の変異型アデノウイルス。 61.前記のトランスジーンがヒト・ホスホグリセレートキナーゼプロモーターの 制御下で発現される、請求項21、22、36、55、57または59に記載の 組換えアデノウイルスベクター。 62.前記のトランスジーンがヒト・ホスホグリセレートキナーゼプロモーターの 制御下で発現される、請求項26または28に記載の組換えアデノ随伴ウイルス ベクター。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33368094A | 1994-11-03 | 1994-11-03 | |
US333,680 | 1994-11-03 | ||
PCT/US1995/014793 WO1996014061A1 (en) | 1994-11-03 | 1995-11-03 | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008064188A Division JP2008200043A (ja) | 1994-11-03 | 2008-03-13 | 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508491A true JPH10508491A (ja) | 1998-08-25 |
JP4167725B2 JP4167725B2 (ja) | 2008-10-22 |
Family
ID=23303814
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51554296A Expired - Fee Related JP4167725B2 (ja) | 1994-11-03 | 1995-11-03 | 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 |
JP2008064188A Withdrawn JP2008200043A (ja) | 1994-11-03 | 2008-03-13 | 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008064188A Withdrawn JP2008200043A (ja) | 1994-11-03 | 2008-03-13 | 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US5872005A (ja) |
EP (1) | EP0797436B1 (ja) |
JP (2) | JP4167725B2 (ja) |
KR (1) | KR970706806A (ja) |
AT (1) | ATE320271T1 (ja) |
AU (2) | AU4109296A (ja) |
CA (1) | CA2204357C (ja) |
DE (1) | DE69534878T2 (ja) |
WO (1) | WO1996014061A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012050453A (ja) * | 1995-11-09 | 2012-03-15 | Genzyme Corp | 組換えaavビリオン産生における使用のための補助機能 |
JP2023500996A (ja) * | 2020-01-16 | 2023-01-17 | ジェイムズ ダブリュー. ヒル, | 遺伝子導入による眼色の変更 |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0710288B1 (en) * | 1993-06-10 | 2006-04-05 | Genetic Therapy, Inc. | Adenoviral vectors for treatment of hemophilia |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
CA2192442C (en) | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
ES2240980T3 (es) * | 1994-10-28 | 2005-10-16 | The Trustees Of The University Of Pennsylvania | Adenovirus mejorado y metodos de utilizacion del mismo. |
WO1996018418A1 (en) * | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
US6287557B1 (en) * | 1995-02-21 | 2001-09-11 | Cantab Pharmaceuticals Research Limited | Methods of gene therapy using herpes viral vectors expressing GM-CSF |
US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
US5756283A (en) * | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
US6281010B1 (en) * | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
EP0844887B1 (en) * | 1995-06-07 | 2009-12-23 | University Of North Carolina At Chapel Hill | Aav transduction of myoblasts |
US6040183A (en) * | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) * | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6265212B1 (en) * | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
FR2737222B1 (fr) * | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
EP1983057A3 (en) * | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5846528A (en) | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5962313A (en) | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
DE19620687A1 (de) * | 1996-05-22 | 1997-11-27 | Centeon Pharma Gmbh | Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo |
JP2000515504A (ja) * | 1996-07-05 | 2000-11-21 | フィリップ イー. ブラントン | 細胞死を誘導するアデノウイルスe4蛋白質 |
US6730662B1 (en) | 1996-07-05 | 2004-05-04 | Mcgill University | Adenovirus E4 proteins for inducing cell death |
EP2221361A3 (en) | 1996-08-30 | 2011-02-09 | Life Technologies Corporation | Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium |
JP2001500015A (ja) * | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
AU4624197A (en) * | 1996-09-25 | 1998-04-17 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
DE19644500C2 (de) * | 1996-10-25 | 1998-11-05 | Deutsches Krebsforsch | AAV-DNA mit Helfervirus-Sequenzen |
WO1998032860A1 (en) * | 1997-01-28 | 1998-07-30 | Baxter International Inc. | Methods for highly efficient generation of adenoviral vectors |
US6403370B1 (en) | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
US6100086A (en) | 1997-04-14 | 2000-08-08 | Genzyme Corporation | Transgene expression systems |
US20030125278A1 (en) * | 1997-08-13 | 2003-07-03 | Tang De-Chu C. | Immunization of animals by topical applications of a salmonella-based vector |
US20030045492A1 (en) * | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
US6348450B1 (en) * | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
AU734290B2 (en) * | 1997-10-29 | 2001-06-07 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP2001526900A (ja) | 1997-12-23 | 2001-12-25 | イントロヘーネ ベスローテン フェンノートシャップ | 標的細胞の染色体dnaへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス |
ES2235470T3 (es) * | 1998-03-20 | 2005-07-01 | The Trustees Of The University Of Pennsylvania | Composiciones y metodos para la produccion libre de cooperadores de virus adnoasociados recombinantes. |
US6953690B1 (en) | 1998-03-20 | 2005-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO1999057296A1 (en) * | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US6200560B1 (en) * | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
JP2002538770A (ja) * | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ウイルスベクターとその製造及び投与の方法 |
JP4693244B2 (ja) | 1999-03-18 | 2011-06-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法 |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
US6864235B1 (en) * | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US6911429B2 (en) * | 1999-04-01 | 2005-06-28 | Transition Therapeutics Inc. | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
US20040009936A1 (en) * | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
US6495360B1 (en) * | 1999-05-28 | 2002-12-17 | Photogen, Inc. | Method for enhanced protein stabilization and for production of cell lines useful for production of such stabilized proteins |
AU1453501A (en) * | 1999-11-10 | 2001-06-06 | Genzyme Corporation | Ptp/dna polymerase cell line as packaging cell line for minimal adenoviral vectors |
WO2001083797A2 (en) | 2000-04-28 | 2001-11-08 | Avigen, Inc. | Polynucleotides for use in recombinant adeno-associated virus virion production |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
CA2422882A1 (en) * | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
US6916635B2 (en) * | 2000-10-02 | 2005-07-12 | The Research Foundation Of State University Of New York | Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof |
AU2002329176A1 (en) * | 2001-05-25 | 2002-12-23 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
US6682929B2 (en) | 2001-07-23 | 2004-01-27 | Genvec, Inc. | Adenovector complementing cells |
KR100432953B1 (ko) * | 2001-09-01 | 2004-05-28 | 김주항 | 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스 |
WO2003022311A1 (en) * | 2001-09-13 | 2003-03-20 | Genvec, Inc. | Adenoviral vector and related system and methods of making and use |
US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US20030198620A1 (en) * | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
US7090836B2 (en) * | 2002-06-21 | 2006-08-15 | Institut Pasteur | Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal |
CA2421269A1 (en) | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
JP4644663B2 (ja) * | 2003-06-03 | 2011-03-02 | セル ジェネシス インコーポレイテッド | ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法 |
WO2005056762A2 (en) * | 2003-12-05 | 2005-06-23 | University Of Iowa Research Foundation | Truncated cmv promoters and vectors containing same |
US20060057127A1 (en) * | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
US7892809B2 (en) * | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
WO2006091722A2 (en) * | 2005-02-23 | 2006-08-31 | Uab Research Foundation | Alkyl-glycoside enhanced vaccination |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
AU2006272706A1 (en) * | 2005-07-21 | 2007-02-01 | Abbvie Inc. | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
WO2009032256A2 (en) * | 2007-08-30 | 2009-03-12 | Cell Genesys, Inc. | Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
MX2010012592A (es) | 2008-05-20 | 2011-05-05 | Eos Neuroscience Inc | Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas. |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
MX2012005117A (es) | 2009-10-30 | 2012-06-14 | Abbott Lab | Construcciones de sorf y expresion de gen multiple. |
CA2783010C (en) * | 2009-12-08 | 2020-06-16 | Memorial Sloan-Kettering Cancer Center | Method and composition to increase radiation-induced tumor therapeutic effects |
SG10201603896RA (en) | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
CA3234028A1 (en) | 2014-03-11 | 2015-09-17 | Wayne State University | A modified mglur6 promoter and methods of use |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
WO2017024000A1 (en) | 2015-08-03 | 2017-02-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
ES2907486T3 (es) | 2015-09-24 | 2022-04-25 | Univ North Carolina Chapel Hill | Métodos y composiciones para reducir metástasis |
CN109196106A (zh) | 2016-03-28 | 2019-01-11 | 维度治疗公司 | 腺病毒的热灭活方法 |
EP3526321A4 (en) | 2016-10-14 | 2020-05-13 | Ultragenyx Pharmaceutical Inc. | USE OF TONIFYING AGENTS TO IMPROVE THE YIELD OF RECOMBINANT ADENO-ASSOCIATED VIRUS |
EP3601581A4 (en) | 2017-03-22 | 2021-05-19 | Ultragenyx Pharmaceutical Inc. | CELL CULTURE METHODS USING HDAC INHIBITORS OR REP PROTEINS |
WO2021028837A1 (en) | 2019-08-13 | 2021-02-18 | Waters Technologies Corporation | Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
JP2023545731A (ja) | 2020-10-07 | 2023-10-31 | アスクレピオス バイオファーマシューティカル, インコーポレイテッド | 肢帯型2i(lgmd2i)を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質(fkrp)の治療的アデノ随伴ウイルス送達 |
WO2023069882A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se |
EP4419679A1 (en) | 2021-10-20 | 2024-08-28 | University of Rochester | Methods and compositions for rejuvenating cns glial populations by suppression of transcription factors |
WO2023150553A1 (en) | 2022-02-01 | 2023-08-10 | University Of Rochester | Gpr17 promoter-based targeting and transduction of glial progenitor cells |
WO2023150557A1 (en) | 2022-02-01 | 2023-08-10 | University Of Rochester | Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
AU7906691A (en) * | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
EP1024198A3 (en) * | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
-
1995
- 1995-05-12 US US08/439,586 patent/US5872005A/en not_active Expired - Fee Related
- 1995-11-03 DE DE69534878T patent/DE69534878T2/de not_active Expired - Fee Related
- 1995-11-03 AU AU41092/96A patent/AU4109296A/en not_active Abandoned
- 1995-11-03 EP EP95939149A patent/EP0797436B1/en not_active Expired - Lifetime
- 1995-11-03 CA CA002204357A patent/CA2204357C/en not_active Expired - Fee Related
- 1995-11-03 AT AT95939149T patent/ATE320271T1/de not_active IP Right Cessation
- 1995-11-03 JP JP51554296A patent/JP4167725B2/ja not_active Expired - Fee Related
- 1995-11-03 WO PCT/US1995/014793 patent/WO1996014061A1/en active IP Right Grant
-
1997
- 1997-05-03 KR KR1019970703020A patent/KR970706806A/ko not_active Application Discontinuation
-
1999
- 1999-12-31 AU AU65571/99A patent/AU756629B2/en not_active Ceased
-
2008
- 2008-03-13 JP JP2008064188A patent/JP2008200043A/ja not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012050453A (ja) * | 1995-11-09 | 2012-03-15 | Genzyme Corp | 組換えaavビリオン産生における使用のための補助機能 |
JP2023500996A (ja) * | 2020-01-16 | 2023-01-17 | ジェイムズ ダブリュー. ヒル, | 遺伝子導入による眼色の変更 |
US11622927B2 (en) | 2020-01-16 | 2023-04-11 | James W. Hill | Changing eye color by gene transduction |
Also Published As
Publication number | Publication date |
---|---|
AU4109296A (en) | 1996-05-31 |
DE69534878T2 (de) | 2006-11-16 |
WO1996014061A1 (en) | 1996-05-17 |
AU756629B2 (en) | 2003-01-16 |
JP4167725B2 (ja) | 2008-10-22 |
JP2008200043A (ja) | 2008-09-04 |
AU6557199A (en) | 2000-03-23 |
CA2204357C (en) | 2007-09-11 |
EP0797436A1 (en) | 1997-10-01 |
EP0797436A4 (en) | 1999-09-08 |
ATE320271T1 (de) | 2006-04-15 |
DE69534878D1 (de) | 2006-05-11 |
US5872005A (en) | 1999-02-16 |
CA2204357A1 (en) | 1996-05-17 |
EP0797436B1 (en) | 2006-03-15 |
KR970706806A (ko) | 1997-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4167725B2 (ja) | 新規なアデノウイルスベクター、パッケージング細胞系、組換えアデノウイルスおよび方法 | |
WO1996014061A9 (en) | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods | |
US20020168342A1 (en) | Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods | |
KR100403708B1 (ko) | 재조합아데노-수반바이러스(aav)제조방법및이의용도 | |
KR100510822B1 (ko) | 재조합 아데노바이러스 제조용 세포 | |
JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
AU759573B2 (en) | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal DNA of target cells | |
US5981225A (en) | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same | |
US5851806A (en) | Complementary adenoviral systems and cell lines | |
US5871726A (en) | Tissue specific and tumor growth supperssion by adenovirus comprising prostate specific antigen | |
JP4051416B2 (ja) | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム | |
JPH11507240A (ja) | 組み換えアデノウイルス及びアデノ随伴ウイルス、細胞株、並びに生産方法並びにその使用 | |
US6475480B1 (en) | Use of adenoviral E4 reading frames to improve expression of a gene of interest | |
JPH11503910A (ja) | アデノウイルスヘルパーウイルスシステム | |
US5985846A (en) | Gene therapy for muscular dystrophy | |
US20060008884A1 (en) | Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof | |
KR100484441B1 (ko) | IVa2유전자가불활성화된결손재조합아데노바이러스 | |
JPH11506311A (ja) | 遺伝子治療用のアデノウイルスベクター | |
EP1252321A1 (en) | Replication deficient adenovirus vectors | |
AU765709B2 (en) | Gene therapy for cystic fibrosis | |
CZ413199A3 (cs) | Způsob výroby adenovirových vektorů nepatřících do skupiny C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060906 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070403 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070409 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080715 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080804 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110808 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |